Skip to main content

Advertisement

SpringerLink
Log in

An Aggressive Approach to Extrahepatic Cholangiocarcinomas Is Warranted: Margin Status Does Not Impact Survival after Resection

  • Hepatic and Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

With cholangiocarcinoma, the only hope of a cure is resection. This study was undertaken to determine the impact of margin status, stage, tumor location, and adjuvant therapy on survival after resection of extrahepatic cholangiocarcinoma.

Methods

From 1985–2006, 91 patients underwent resections of cholangiocarcinomas. Margin status was codified as micro-/macroscopically negative, microscopically positive/ macroscopically negative, or micro-/macroscopically positive. Stage was determined using the AJCC classification (6th edition). Tumor location was classified as proximal, mid, or distal. Proximal tumors were resected by extrahepatic biliary resection with/without concomitant hepatic resection (n = 48), distal extrahepatic cholangiocarcinomas by pancreaticoduodenectomy (n = 35), and mid tumors by extrahepatic biliary resection alone (n = 8). Regression analysis and survival curve analysis were utilized. Data are presented as median, mean ± standard deviation (SD).

Results

Overall survival after resection was 21 months, 38 ± 46.0. Survival was not impacted by margin status (R0 20 months, 35 ± 45.1 versus R1 32 months, 45 ± 49.4). AJCC stage inversely correlated with survival (p = 0.004, Spearman regression analysis). Tumor location did not impact upon survival (p = 0.57, log-rank test). For proximal tumors, survival after biliary resection was significantly impacted by the need for concomitant hepatectomy (15 months, 27 ± 31.4 versus 41 months, 67 ± 17.1). Utilization of adjuvant therapy significantly improved survival (33 months, 56 ± 63.1 versus 19 months, 33 ± 40.0) (p = 0.046, Spearman regression).

Conclusions

Survival after resection of extrahepatic cholangiocarcinoma is significantly impacted by AJCC stage, the use of adjuvant therapy, and in patients with proximal tumors, the need for concomitant hepatectomy. Margin status and tumor location do not impact survival. Cholangiocarcinomas should be aggressively resected irrespective of tumor location, even if resection might result in microscopically positive margins, and adjuvant therapy applied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Shimada H, Nimoto S, Nakagawara G, et al. Infiltration of bile duct carcinoma along the wall. Nippon Geka Gakkai Zasshi 1985;86:179–86

    PubMed  CAS  Google Scholar 

  2. Nordback IH, Pitt HA, Coleman J, et al. Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 1994;115:597–603

    PubMed  CAS  Google Scholar 

  3. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer: high resectability rate and 5-year survival. Ann Surg 1999;230:266–75

    Article  PubMed  CAS  Google Scholar 

  4. Kosuge T, Yamamoto J, Shimnada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663–71

    Article  PubMed  CAS  Google Scholar 

  5. Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385–94

    Article  PubMed  CAS  Google Scholar 

  6. Nagino M, Nimura Y, Kamiya J, et al. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998;45:7–13

    PubMed  CAS  Google Scholar 

  7. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710–1717

    PubMed  CAS  Google Scholar 

  8. Kaya M, de Groso P, Angulo P, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroentrol 2001;96:1164–9

    Article  CAS  Google Scholar 

  9. Johnson KJ, Ohiff JF, Ohiff SP. The presence and significance of lymphadenopaty detected by CT in primary sclerosing cholangitis. Br J Radiol 1998;71:1279–82

    PubMed  CAS  Google Scholar 

  10. Tesana S, Takabashi Y, Sitbithaworn P, et al. Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunize Syrian golden hamsters infected with O. Viverrini and administered dimethylnitrosamine. Parasitol Int 2000;49:239–51

    Article  PubMed  CAS  Google Scholar 

  11. Kubo S, Kinoshita H, Hirohashi K, et al. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995, 639–41

  12. Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000;232:166–74

    Article  PubMed  CAS  Google Scholar 

  13. Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000;7:155–62

    Article  PubMed  CAS  Google Scholar 

  14. Saldinger PF, Blumgart LH. Resection of hilar cholangiocarcinoma: a European and United States experience. J Hepatobiliary Pancreat Surg 2000;7:111–4

    Article  PubMed  CAS  Google Scholar 

  15. Tabata M, Kawarada Y, Yokoi H, et al. Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2000;7:148–54

    Article  PubMed  CAS  Google Scholar 

  16. Gazzaniga GM, Filauro M, Bagarolo C, et al. Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg 2000;7:122–7

    Article  PubMed  CAS  Google Scholar 

  17. Launois B, Reding R, Lebeau G, et al. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 2000;7:128–34

    Article  PubMed  CAS  Google Scholar 

  18. Blom D, Schwartz SI. Surgical treatment and outcomes in carcinoma of the Extrahepatic bile ducts: the University of Rochester experience. Arch Surg 2001;136:209–14

    Article  PubMed  CAS  Google Scholar 

  19. Lee SG, Lee YJ, Park KM, et al. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg 2000;7:135–41

    Article  PubMed  CAS  Google Scholar 

  20. Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma; the Johns Hopkins approach. J Hepatobiliary Pancreat Surg 2000;7:115–21

    Article  PubMed  CAS  Google Scholar 

  21. Zervos E, Osborne D, Goldin S, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005;190:810–5

    Article  PubMed  Google Scholar 

  22. Zervos E, Pearson H, Durkin A, et al. In-continuity hepatic resection for advanced hilar cholangiocarcinoma. Am J Surg 2004;188:584–8

    Article  PubMed  Google Scholar 

  23. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–75

    Article  PubMed  CAS  Google Scholar 

  24. Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 2000;7:55–66

    Article  PubMed  CAS  Google Scholar 

  25. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, respectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–17

    Article  PubMed  CAS  Google Scholar 

  26. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for Hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004;139:514–23

    Article  PubMed  Google Scholar 

  27. Hejna M, Pruckmayer M, Raderer M, et al. The role of chemotherapy and radiation in the management of biliary cancer; a review of the literature. Eur J Cancer 1998;34:977–86

    Article  PubMed  CAS  Google Scholar 

  28. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful in gallbladder carcinoma? Cancer 2002;95:1685–95

    Article  PubMed  Google Scholar 

  29. Malik IA, Aziz Z, Zaida SH, et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003;26:174–7

    Article  PubMed  CAS  Google Scholar 

  30. Patt YZ, Hassan M, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578–86

    Article  PubMed  CAS  Google Scholar 

  31. Pitt H, Nakeeb A, Abrams R, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–97

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of South Florida College of Medicine, Tampa General Hospital, Room F145, 1289, Tampa, FL, 33601, USA

    Jonathan Hernandez MD, Sarah M. Cowgill MD, Sam Al-Saadi MD, Desiree Villadolid MPH, Sharona Ross MD, Emily Kraemer, Mark Shapiro, John Mullinax BS, Jennifer Cooper BS, Steven Goldin MD, PhD, Emmanuel Zervos MD & Alexander Rosemurgy MD

Authors
  1. Jonathan Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah M. Cowgill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sam Al-Saadi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Desiree Villadolid MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sharona Ross MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emily Kraemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mark Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John Mullinax BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jennifer Cooper BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Steven Goldin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Emmanuel Zervos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alexander Rosemurgy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Rosemurgy MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernandez, J., Cowgill, S.M., Al-Saadi, S. et al. An Aggressive Approach to Extrahepatic Cholangiocarcinomas Is Warranted: Margin Status Does Not Impact Survival after Resection. Ann Surg Oncol 15, 807–814 (2008). https://doi.org/10.1245/s10434-007-9756-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9756-2

Keywords

Search

Navigation